- Bristol Myers Squibb is a company that has undergone an extensive transformation and as a result, has reinvented itself
- Once a company consisting of multiple and vastly different business units, it is now the largest diversified specialty global biopharma company
- Its mission and focus is to utilize innovation to advance the treatment of serious disease and significant unmet medical need
- This organizational evolution required substantial change for the product development and manufacturing arms of the company
- Technology, systems, processes, people and culture all needed to be re-evaluated through a “new lens”
- The presentation will cover this journey including approach, successes, lessons learned and what’s next
—
EVP and President, Global Product Development & Supply
Bristol-Myers Squibb
As Executive Vice President and President of Global Product Development and Supply (GPS), Lou oversees the worldwide product development, manufacturing and supply chain arms for Bristol-Myers Squibb (BMS). His organization leads the development, launch and commercial lifecycle of an innovative portfolio of products that accelerate science and deliver hope to patients through life-changing medicines.
Lou joined BMS in 2011 as President of Technical Operations. Prior to joining BMS, he led Pfizer’s worldwide biotech manufacturing operations as Senior Vice President of the Specialty-Biotechnology Operating Unit. Previously, he was responsible for global pharmaceutical manufacturing for Wyeth and Vice President of Quality for Hoffman-LaRoche.
Lou is an active member and has held leadership positions in several industry organizations including the Pharmaceutical Research and Manufacturers of America (PhRMA), International Society of Pharmaceutical Engineering (ISPE) and National Association of Manufacturers (NAM).
He holds a bachelor’s degree in pharmacy from Temple University and a master’s in management from Webster University.
